Additional Information

Description

Fluad® 2025–2026 (Flu-113) is a trivalent inactivated influenza vaccine designed for individuals aged 65 years and older. This vaccine is specifically formulated with an adjuvant, MF59, to enhance the immune response in older adults, who may have a weaker immune response to standard influenza vaccines. The vaccine contains hemagglutinin antigens from two influenza A strains and one influenza B strain, in line with the World Health Organization (WHO) recommendations for the 2025–2026 flu season.

The product is presented in 0.5 mL prefilled syringes, with each box containing 10 single-dose units. Fluad® is administered via intramuscular injection, typically into the deltoid muscle. This formulation is preservative-free and does not require reconstitution, ensuring ease of administration for healthcare professionals.

Common side effects of Fluad® include pain, redness, or swelling at the injection site, as well as mild systemic symptoms such as fever, headache, and fatigue. Serious adverse reactions are rare but may include severe allergic reactions or Guillain-Barré syndrome. The vaccine is contraindicated in individuals with a history of severe allergic reactions to any vaccine component.